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There is a growing need for models of human diseases that utilise native, donated 
human tissue in order to model disease processes and develop novel therapeutic 
strategies. In this paper we assessed the suitability of aged human retinal explants as 
a potential model of chronic retinal ganglion cell (RGC) degeneration. Our results 
confirmed that RGC markers commonly used in rodent studies (NeuN, βIII Tubulin and 
Thy-1) were appropriate for labelling human RGCs and followed the expected 
differential expression patterns across, as well as throughout, the macular and para-
macular regions of the retina. Furthermore, we showed that neither donor age nor 
post-mortem time (within 24 hours) significantly affected the initial expression levels 
of RGC markers. In addition, the feasibility of using human post mortem donor tissue 
as a long-term model of RGC degeneration was determined with RGC protein being 
detectable up to 4 weeks in culture with an associated decline in RGC mRNA and 
significant, progressive, apoptotic labelling of NeuN+ cells. Differences in RGC 
apoptosis might have been influenced by medium compositions indicating that media 
constituents could play a role in supporting axotomised RGCs. We propose that using 
ex vivo human explants may prove to be a useful model for testing the effectiveness 
of neuroprotective strategies. 
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Organotypic retinal cultures provide an important link between dissociated cell cultures 
and in vivo models (Johnson et al., 2011), benefiting from maintenance of 
heterogeneous cell populations that can be observed in situ (Caffé et al., 2001). 
Although cultures of dissociated cells are helpful in elucidating the direct effect of drugs 
on individual cell types, the loss of intercellular relationships limits their usefulness 
when modelling complex diseases (Buyens et al., 2014). At the other end of the 
spectrum, animal models that more closely resemble actual pathologies are costly, 
time consuming and the outcomes can be difficult to correlate with human conditions. 
Furthermore, there is a recognized demand for in vitro models that can replace or 
reduce the need for animal experiments. 
 
Although research using retinal explants has increased over recent years, the use of 
human retinal explants is still underutilised. Research using rodent retinal organotypic 
cultures is now common but it is recognised that differences exist between rodent and 
human retina (Albrecht May, 2008; Bobu et al., 2008; Levkovitch-Verbin, 2004). The 
most significant difference between mouse and human retina is that the human retina 
has a central macula and fovea for high-resolution colour vision, in addition to different 
ratios of cone and rod photoreceptors with specific topography and subtypes of retinal 
ganglion cells (RGCs). Using human retina therefore, provides the most appropriate 
tissue to model a variety of human eye diseases.  
 
Some of the factors limiting the advancement of human retinal models are that 
questions remain to be answered regarding donor variability, the effects of post 
mortem time and the potential time scale that the human retina can survive in culture. 
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There are also practical issues to consider, such as whether markers used in animal 
experiments are appropriate for use in human research. The present paper aimed to 
investigate these questions.  
 
Firstly, the expression and labelling of numerous RGC markers was investigated 
across the human retina within the macular and para-macular regions. In addition, the 
variation of RGC mRNA expression was evaluated from numerous post mortem donor 
eyes to address concerns relating to donor variability. Further work to address possible 
effects of post mortem time on tissue viability were assessed through the comparison 
of retina derived immediately after orbital exenteration from living donors and those 
from eyes obtained at varying times after donor patient death. Secondly, we aimed to 
assess the feasibility of using adult human retina in a long-term culture system for 
studying RGC degeneration. We have previously shown that adult human organotypic 
retinal cultures (HORCs) can be used to investigate RGC death following brief 
ischaemic injury (Niyadurupola et al., 2013; Osborne et al., 2015) and glutamate 
excitotoxicity (Niyadurupola et al., 2011), but degeneration over time points longer 
than 48 hours had not been investigated. Human embryonic (Engelsberg et al., 2008) 
and foetal (Donovan and Dyer, 2006; Rojas et al., 2003; Zhang et al., 2010) retinal 
explants have been cultured for up to 42 days with preservation of tissue 
cytoarchitecture and most intraretinal connections. Furthermore, various retinal cell 
markers are still observable in adult human explants after 9 days in culture 
(Fernandez-Bueno et al., 2012). However, RGC degeneration over prolonged periods 




Understanding ways to model and possibly delay the onset of RGC apoptosis will play 
an important role in limiting the effects of optic nerve atrophy and aid in the 
advancement of future regenerative strategies to promote axon regrowth that require 






2 Materials and Methods 
2.1 Human explant dissection and culture 
Donor human eyes were obtained within 24 hours post mortem from the East Anglian 
Eye Bank or within 2 hours from patients undergoing orbital exenteration under the 
auspices of the Human Tissue Bank (both facilities within the Norfolk and Norwich 
University Hospital). All donated material was free of any known retinal pathology and 
contained no obvious ocular trauma or undiagnosed retinal injury at dissection. Fifty-
two post mortem donor eyes were used in this study between the age of 30 and 91 
years. Unpublished data from a larger cohort of untreated eyes (n=100 donor eyes) 
was also included for comparative purposes. The four living donor eyes were kindly 
donated from patients between 59 and 84 years of age. The research was approved 
by the UK National Research Ethics Committee (REC 04/Q0102/57) and was 
conducted under the tenets of the Declaration of Helsinki.  
 
Retinal dissection was performed as described previously (Niyadurupola et al., 2011). 
Briefly, the anterior portion (including the lens and iris) of each donor eye was removed 
carefully by a circumferential incision at the pars plana (Fig. 1A). A flat retinal 
preparation was established by removal of the vitreous and cutting small incisions in 
the peripheral retina (Fig. 1D). The macula removed using a 4mm diameter dissecting 
trephine (Biomedical Research Instruments, MD, USA) (Fig. 1E) and five para-macular 
explants, termed human organotypic retinal cultures (HORCs), were dissected from 
each donor retina using the same trephine. The location of each retinal HORC explant 
was equidistant from the macula for each donor retina using a template to reduce 




4mm circular explants were randomised prior to culture for up to 4 weeks in 35mm 
culture dishes (Corning, NY, USA) containing 1.5ml of freshly prepared medium. 
Culture medium included 1) serum free (SF) Dulbecco’s Modified Eagle Medium 
(DMEM)/HamF12, 2) 10% foetal bovine serum (10% FBS) supplemented 
DMEM/HamF12 or 3) Neurobasal®-A media (NB) with 2% B27 supplement, 1% N2 
supplement and 0.8mM L-glutamine (All from Invitrogen, Paisley, UK). All media were 
supplemented with gentamicin (50 µg/ml; Sigma-Aldrich, Poole, UK) and explants 
were cultured at 35°C in a humidified atmosphere of 95% air/5% CO2. Explants were 
cultured as free-floating preparations, immersed in medium, the RGC side facing 
upwards. Media was replaced immediately after dissection and half the medium was 
exchanged twice weekly thereafter. 
 
2.2 Planar retinal sectioning 
4mm retinal explants were taken from the macular and para-macular retina of 4 donor 
eyes, placed RGC side up on filter paper and mounted on a prepared surface of frozen 
optimal cutting temperature compound (OCT) (Sakura Finetek, Zoeterwoude, 
Netherlands) as described previously (Niyadurupola et al., 2013). Further OCT was 
used to cover the sample prior to freezing. 20µm sections in the plane of the retinal 
nuclear layers were taken using a Bright OTF 5000 cryostat (Bright Instruments, 
Huntingdon, UK) and individually collected in 1.5ml eppendorfs before being frozen on 
dry ice. 
 
2.3 Quantitative Real Time PCR (qRT-PCR) 
Total RNA was extracted from 221 HORCs using the RNeasy Mini Kit (Qiagen, 
Crawley, UK) or from 107 planar retinal sections using the RNeasy Micro kit (Qiagen, 
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Crawley, UK) according to the manufacturer’s instructions. The concentration of RNA 
was measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, USA) and reverse transcribed to complementary DNA 
(cDNA) in a reaction catalysed by Superscript™ II reverse transcriptase with dNTP 
mix and random primers (all Invitrogen, Paisley, UK). 
 
TaqMan PCR was performed using an ABI Prism 7700 Sequence Detection System 
(Applied Biosystems, Warrington, UK) using 5ng of input cDNA, Mastermix (Applied 
Biosystems, Warrington, UK) and probes/primers listed in Table. 1. Whole explant 
mRNA expression was normalised to the geometric mean of CT values for cytochrome 
c-1 (CYC1) and topoisomerase DNA I (TOP1) as described previously (Niyadurupola 
et al., 2011), whilst planar sections were normalised to the section containing the 
greatest level of expression. Expression profiles from individual retinas were aligned 
by matching expression of the photoreceptor marker recoverin (RCVRN). 
 
2.4 Immunohistochemistry and TUNEL analysis 
Immunohistochemistry was used to localise and quantify RGC number. 65 explants 
were fixed in 4% formaldehyde for 24 hours and then cryopreserved in a 30% sucrose 
solution in PBS at 4°C for a further 24 hours. Explants were embedded in OCT and 
frozen at -80°C. Transverse 13µm sections were cut via cryostat and mounted on 
3’aminopropyl-triethoxyl silane (TESPA, Sigma-Aldrich, Poole, UK) coated glass 
slides. 
 
Sections were immunostained overnight with RGC markers neuronal nuclei (NeuN) 
(mouse; 1:250, Millipore, Watford, UK), βIII tubulin (mouse; 1:1000, G7121 Promega, 
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Southampton, UK or rabbit; 1:1000 MRB-435 Covance, Maidenhead, UK) or Thy-1.1 
(mouse; 1:100, Millipore, Watford, UK) diluted in blocking solution (5% goat serum 
(Invitrogen, Paisley, UK), 0.3% Triton X-100 (Sigma-Aldrich, Poole, UK) in PBS). The 
DeadEndTM Fluorometric TUNEL system (TUNEL) (G3250 Promega, Southampton, 
UK) was performed alongside NeuN immunohistochemistry to visualise apoptotic 
RGCs as performed previously (Niyadurupola et al., 2011; Osborne et al., 2015). 
TUNEL staining was carried out the following morning after overnight primary antibody 
incubation according to manufacturer’s instructions. Secondary antibodies of Alexa 
Fluor 488- and 568–conjugated (Invitrogen, Paisley, UK) (1:1000) were used diluted 
in blocking solution for 2 hours and nuclei were counterstained with DAPI (1:100; 
Invitrogen, Paisley, UK).  
 
10 whole-mount explants were fixed in 4% paraformaldehyde for 24 hours followed by 
5x PBS washes and blocking (5% goat serum, 0.2% bovine serum albumin (Sigma-
Aldrich, Poole, UK), 0.3% Triton X-100 in PBS) for 1 hour. Co-localisation between 
(NeuN) (1:200 Millipore) and βIII tubulin (1:1000 Covance) was performed via 
overnight sequential staining using antibodies raised in different species. Following 
washing and secondary antibody staining, whole-mounts were placed on slides, RGC 
side up, between two thin plastic parafilm strips (Sigma-Aldrich, Poole, UK) running 
along either edge of the slide to act as spacers. Samples were then mounted with 
fluorSave™ reagent (Calbiochem/EMD Chemicals Inc., Gibbstown, NJ, USA) and a 
coverslip placed on top. 
 
Images were taken using a wide-field Axiovert 200M fluorescence microscope (Zeiss, 
Welwyn Garden City, UK) or SP5 confocal microscope (Leica Microsystems, Wetzlar, 
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Germany) at 20 or 40X magnification. Confocal images were obtained via sequential 
scanning using 0.5µm z-step intervals. 
 
The number of DAPI-labelled nuclei in the RGC layer was quantified using the ImageJ 
plugin ‘Image-based Tool for Counting Nuclei (ITCN)’ 
(http://www.bioimage.ucsb.edu/downloads/automatic-nuclei-counter-plug-in-for-
imagej). Software accuracy was >95% comparable to manual counts and any missed 
nuclei were added using the ‘Cell Counter’ Plugin. RGC counting and the number of 
TUNEL+ NeuN labelled cells were assessed manually by a masked investigator from 
20 non-overlapping regions per explant. Co-localisation was assessed using Velocity 
software with an acceptance reading of >0.9 between the two fluorescent dyes. The 
images shown were from a stack depth of 3µm where clear distinction between 
individual RGCs could be observed. 
 
2.5 Statistical Analysis 
Data shown is the mean ± standard error of the mean (s.e.m). Significance was 
determined using Student’s t-tests or one-way ANOVA with Dunnett’s or Tukey’s post 
hoc test (GraphPad Prism; Graph-Pad Software Inc., La Jolla, Ca, USA). Differences 





3.1 RGC marker gene expression in retinal explants 
As an indicator of RGC number, the mRNA expression pattern of three commonly 
used RGC markers (RBFOX3, TUB3 and THY1) in human retinal explants (Fig. 2) was 
investigated. Comparable levels of RGC gene expression were seen in each of the 
five para-macular explants (no significant differences between explants were 
observed based on their sampling distribution, RBFOX3 p=0.8480, TUB3 p=0.9761, 
THY1 p=0.9196, Fig. 2B, C, D). The macula (M), as expected, showed the greatest 
expression of each marker.  
 
To address concerns relating to donor variability with respect to post mortem time, we 
compared RGC gene expression from post mortem samples to that of explants from 
living donors, when retinal tissue had been obtained as quickly as possible (<2 hours) 
following orbital exenteration. Results indicated no significant differences in retinal 
RBFOX3, TUB3 and THY1 expression between the living donor samples and those 
excised from post mortem tissue (Fig. 2 – red dots). 
 
Further comparisons to assess RGC variations with age were carried out by plotting 
individual explant gene expression data points against age, which yielded no 
significant correlation (Fig. 3A, C, E). A similar lack of correlation was observed when 
comparing RBFOX3, TUB3 and THY1 to post mortem time (Fig. 3B, D, F). Addressing 
these issues further by comparing THY1 expression from explants collected from 100 
post mortem donor eyes revealed the same outcome that neither age (p=0.0911, Fig. 
3G) nor post mortem time (p=0.8251, Fig. 3H) had any significant influence on RGC 




3.2 RGC mRNA expression profiling in para-macular and macula explants 
To confirm that the investigated RGC markers were expressed in the correct region of 
the retina, planar sectioning was used. RBFOX3, TUB3 and THY1 each showed 
highest expression in the inner retina for both macular and para-macular explants (Fig. 
4). As expected, the macular section yielded of a larger number of sections 
(approximately 20 compared to 10 at the para-macular locations) due to greater retinal 
thickness (Fig. 4A). Of the macular sections, a larger number contained RGC mRNA 
(approximately 8 compared to 4 at the para-macular locations) resulting in a broader 
peak compared to para-macular regions (Fig. 4B). A similar expression pattern was 
seen between each of the three RGC markers, which indicated that the markers were 
likely to be recognising the same cell type. 
 
3.3 Comparison of RGC protein markers in retinal explants 
Having shown that RBFOX3, TUB3 and THY1 represented useful markers for human 
RGCs, being differentially expressed across and throughout the retina in their 
expected locations, we wished to support this data via observation of their protein 
expression.  
 
NeuN, βIII tubulin and Thy-1 immunohistochemistry in both macular and para-macular 
human retinal explants supported gene expression data with almost exclusive labelling 
within the RGC layer (RGCL) (Fig. 5A-C). Using single antibody staining, all DAPI+ 
cells in the RGC layer were counted and the proportions of these cells that were 
positive for each RGC marker was quantified. In macular samples, 82.7±1.9% of DAPI 
stained cells were NeuN+, 80.9±2.6% βIII Tubulin+ and 81.8±1.5% Thy-1+ (Fig. 5Ai, Bi, 
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Ci and Table. 2). In para-macular regions, respective RGC markers were 53.7±2.3%, 
51.2±0.6% and 52.8±3.3% of all RGCL nuclei (Fig. 5Aii, Bii, Cii and Table. 2). A small 
number of cells in the INL also stained positive for each antibody indicating likely 
displaced RGCs or amacrine cells (Fig. 5A-C). 
 
Co-localisation between NeuN and βIII tubulin was then investigated to ensure that 
the RGC markers were binding to the same cell type within the RGCL. NeuN and βIII 
tubulin were selected over Thy-1 due to more complete and intense staining of the cell 
nuclei and soma, which improved evaluation. Both transverse section and whole-
mount staining confirmed a strong level of co-localisation between the two markers 
with approximately 95% of NeuN+ cells staining for βIII tubulin+ (Fig. 6A-D and Table. 
3). 
 
3.4 RGC survival with long-term culture 
Having shown that NeuN could be used to accurately label RGCs in the human retina, 
the longevity of RGCs in para-macular retinal explants (HORCs) was assessed over 
a four-week period. NeuN immunohistochemistry was chosen as the preferred RGC 
marker to combine with apoptotic labelling due to its discrete staining of the cell body 
which enabled accurate quantification with the nuclei stain TUNEL. Changes in RGC 
gene expression were also assessed throughout the four-week period since these may 
be a more sensitive measure of RGC survival within explants (Niyadurupola et al., 
2013). Of the three comparable RGC gene expression markers, we chose to 
investigate THY1 to coincide with our previous research modelling short-term RGC 





Over four weeks in culture, the overall appearance of HORCs showed no obvious 
structural changes, with explants retaining a considerable degree of histotypic 
organisation throughout long-term culture (Fig. 7A-E). Outer nuclear, inner nuclear and 
RGC nuclei were detectable in specific layers throughout the four-week time frame 
and NeuN+ cells could be detected at all experimental time points. 
 
Quantification of NeuN+ cells at 1 week revealed no significant loss in SF and 10% 
FBS groups (Fig. 7F) although there was a significant decrease in labelled cells at 
subsequent time points (23.0±8.3% SF (n=6 donor eyes), 20.8±5.3% 10% FBS (n=3 
donor eyes) at week 4, p≤0.05, Fig. 7F). Greater RGC loss was measured in HORCs 
cultured in Neurobasal medium (NB) where there was a linear decrease in the number 
of NeuN+ cells, decreasing approximately 25% (25.2±4.2) at week 1 and by 60% 
(59.2±7.5) at week 3 (p≤0.05, n=3 donor eyes, Fig. 7F). Comparisons at 3 and 4 weeks 
revealed significantly fewer RGCs in explants cultured in NB medium compared to 
either SF or 10% FBS medium (p≤0.05, n=3 donor eyes, Fig. 7F). 
 
Assessing the viability of these cells using TUNEL labelling revealed that, although 
RGCs were detectable, the cells were undergoing time-dependent apoptosis. TUNEL-
labelling showed a progressive increase in apoptotic labelling within the RGCL with 
time for all three treatment groups (Fig. 7G). Under all conditions, there was a 
significant increase in the number of TUNEL+ NeuN–labelled nuclei at week 1 
compared to week 0 (n≥3 donor eyes/treatment, p≤0.05, Fig. 7G). TUNEL+ NeuN–
labelling continued to increase at weekly intervals with almost all (82.2±7.1 SF, 
90.4±0.8 10% FBS, 94.4±2.8 NB) NeuN+ cells staining as apoptotic by week 4 (p≤0.05, 
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n≥3 donor eyes/treatment). HORCs taken from a living donor followed a similar trend 
(Fig. 7G). HORCs cultured in NB medium had the most rapid increase in TUNEL 
labelling (76.1±11.2) with a significantly higher number of apoptotic RGCs compared 
to SF (45.0±14.8) and 10% FBS (50.5±12.1) groups at week 1 (p≤0.05, n=3 donor 
eyes/treatment). 
 
THY1 gene expression changes supported a decline in RGC viability with time in 
culture, shown by a rapid decrease in THY1 immediately after dissection (week 0) to 
approximately 20% of the post-dissection level after 1 week (SF n=5, 10% FBS n=5, 
NB n=2 donor eyes, Fig. 7H); expression levels remained at this 20% level for the 
duration of the experiments. An equivalent relative decline in THY1 after 1 week was 
seen in both the retina of the living donor and post mortem material. Culturing explants 
in 10% FBS or NB did not prevent, or accelerate, THY1 mRNA loss with time 





Organotypic culture models have become an increasingly popular experimental tool in 
retinal research, bridging the gap between in vitro and in vivo experimentation. We 
were the first to use the human retina to create a quantifiable explant model that can 
be used to study RGC degeneration (Niyadurupola et al., 2011). In the present study 
we further characterised markers for human RGCs and showed that post mortem 
human organotypic retinal cultures can be used as a long-term model to study RGC 
degeneration after axotomy. 
 
4.1 RGC markers in the human retina 
Firstly we revealed that neuronal markers for monitoring the RGC population in the 
rodent eye could be applied to the human retina, with precise and accurate labelling 
of cell populations within the RGCL. NeuN is widely regarded as being a useful RGC 
marker (Bull et al., 2011; Canola et al., 2007; Dijk et al., 2007; Zhong et al., 2007) and 
strong co-labelling has been detected between the antibody and fluorogold retrograde 
labelled mouse RGCs (Buckingham et al., 2008). Similarly, βIII tubulin has been 
shown to provide a reliable indicator of the number of surviving RGCs in comparisons 
with fluorogold-labelled rat RGCs (Cui et al., 2003). Furthermore, whilst Thy-1 
transgenic animals have been used frequently in glaucoma research (Raymond et al., 
2009). THY1 mRNA levels have been found by us (Niyadurupola et al., 2011) and 
others (Nash and Osborne, 1999) to provide a good index of RGC damage. 
 
We initially showed that RGC mRNA expression across the macular and para-macular 
regions of the retina followed the typical RGC profile for the human retina; with greatest 
expression in the macula, the central region of the human retina, which is responsible 
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for the highest visual acuity. The mRNA expression results were in keeping with our 
previous data, which showed that RBFOX3 (NeuN) mRNA decreased from the central 
macula to the periphery (Niyadurupola et al., 2011). We further demonstrated that, for 
each of the three RGC markers investigated, the same expression profile was 
identified and exhibited a consistent organisation throughout the retina; with minimal 
expression in the outer retina increasing towards maximal expression in the innermost 
retina where the RGC cell bodies are located. 
 
The mRNA expression data was supported by immunohistochemistry for NeuN, βIII 
tubulin and Thy-1 that only labelled cells in the inner retina. NeuN staining was located 
in the cell body (nucleus and surrounding cytoplasm) as has been shown previously 
(Bull et al., 2011; Raymond et al., 2008) whilst βIII tubulin labelled RGC soma and 
their processes, similar to the distribution observed in rodent retinas (Johnson and 
Martin, 2008; Li et al., 2010). Thy-1 is a cell surface glycoprotein that associates with 
the RGC bodies, dendrites and axons (Nash and Osborne, 1999; Osborne and Larson, 
1996; Sheppard et al., 1991) and in our studies labelling was observed primarily on 
the cell bodies. However labelling was diffuse, probably because Thy-1 is a cell 
surface marker and resulted, therefore, in Thy-1 being the most challenging to 
quantify. 
 
Co-localisation of NeuN and βIII tubulin confirmed that either antibody could be used 
as a reliable marker to quantify RGCs. Others have shown that a co-localisation 
pattern also exists for Thy-1 and NeuN whereby 95.4% of thy-1-CFP cells in the RGCL 
also labelled with NeuN (Raymond et al., 2008). In addition, we observed a greater 
proportion of NeuN, βIII tubulin and Thy-1 positive cells within the RGCL of macular 
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samples compared to para-macular samples; this would be in keeping with the 
functional superiority of the central region of the retina with previous estimates 
suggesting that almost all cells in the RGCL at the human fovea are RGCs (only 3% 
representing displaced amacrine cells). In para-macular samples the proportion of 
RGCs in the RGCL decreased to approximately 60%, a similar percentage to that seen 
in mice and rat retina; whereby approximately 50-60% of cells were RGCs with the 
remainder being of amacrine origin (Jeon et al., 1998; Perry, 1981). Although we did 
not measure changes at the periphery, others have shown that the proportion of RGCs 
can decrease to as few as 20%, with the remainder being of amacrine lineage (Curcio 
and Allen, 1990). Sampling at the periphery therefore may contain too few RGCs for 
quantitative neurodegeneration studies. 
 
It should be noted that in rodents βIII tubulin antibodies can cross react with ligands 
expressed on amacrine cells (Sharma and Netland, 2007). Similarly, probing for NeuN 
in rats revealed significant INL staining, likely to be that of amacrine cells (Bull et al., 
2011; Johnson et al., 2014). However, these latter observations were less apparent in 
the human retina with very few NeuN or βIII tubulin-labelled cells being identified 
outside the RGCL. Our results also showed that the proportions of NeuN+ and βIII 
tubulin+ cells closely matched those that were Thy-1+ which has been reported by 
others to exclusively label RGCL cells (Kwong et al., 2010; Liu et al., 2013) or with 
expression levels several fold higher on RGCs than amacrine cells (Raymond et al., 
2009). Furthermore, we believe the appropriateness of these markers can be shown 
by the differential expression between macular and para-macular regions; It is likely 
that regional differences would not be seen if labelling was inclusive of amacrine cells. 
The retinal profiles of THY1 and the cholinergic amacrine marker ChAT also differed 
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in peak expression indicating a likely difference in cell type detection and that we were 
accurately measuring just RGC cells (Supplementary Fig. 1). 
 
4.2 The suitability of using post mortem human retinal tissue 
There has been an assumption that it is not feasible to utilise post mortem retina as a 
model of degeneration due to the extended time from death to retinal isolation. 
Furthermore, whole-mount retinal analysis has demonstrated previously that RGC 
number in the human retina can vary considerably between individuals, particular with 
age (Harman et al., 2000). However, the present results have indicated that RGC 
mRNA expression (the most sensitive indicator of RGC loss) in the area surrounding 
the macula does not show a large degree of variability with age or post mortem time. 
Even when eyes were taken with a very short transit time (<2 hours), and from living 
donors, we did not see a substantial difference in RGC mRNA expression compared 
to aged, long (up to 24 hours) post-mortem time eyes. The rates of THY1 mRNA loss 
and apoptotic labelling also revealed little difference between donors. Thus it can be 
concluded that a rapid degradation of RGC marker mRNA did not occur between 
death/removal of eyes and dissection. Additionally the degeneration of RGCs from 
living donors occurred at the same speed implying rate of damage was comparable 
between tissues. 
 
4.3 Human retinal explants as a model of chronic neurodegeneration 
Our final experiments assessed the feasibility of using adult human retina as a long-
term culture system for studying RGC degeneration. Of the three RGC markers 
investigated, NeuN proved quickest, easiest and most reliable to count. Using 
antibodies to βIII tubulin and Thy-1 led to additional labelling of RGC dendrites and 
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axons making quantification more time consuming. βIII tubulin and Thy-1 have also 
proven difficult to assess in rat explants (Bull et al., 2011) and therefore might not be 
appropriate for large scale analyses. Interestingly, it has been shown that Thy-1 
(Huang et al., 2006) and βIII tubulin expression are down regulated following injury, 
prior to cell loss, which could make NeuN an appropriate RGC marker for 
immunohistochemical identification and quantification, although the others may be 
useful therefore in assessing earlier neurodegenerative changes. 
 
As a model of degeneration, retinal explants require complete RGC axotomy, an insult 
that ultimately leads to RGC death and is associated with in vivo models (Levkovitch-
Verbin et al., 2013; Wang et al., 2015). The progressive nature of RGC loss, therefore, 
can provide a useful model in which to investigate the neurodegenerative features of 
optic nerve degeneration associated with injury or glaucoma.  
 
In our experiments, human explants showed progressive RGC apoptotic labelling with 
time, with minimal damage immediately post dissection, as observed previously 
(Niyadurupola et al., 2011), to extensive RGC apoptotic labelling at 4 weeks. The rate 
of apoptosis closely matched that seen in animal optic nerve crush models (70% of 
RGCs are apoptotic within the first 14 days after injury (Magharious et al., 2011)), 
although HORC RGC death appeared to be faster than in rodent explant models 
(Johnson and Martin, 2008; McKernan et al., 2007). It is unlikely that the species 
differential effect is due to the extended post mortem times seen when using human 
organotypic cultures because: 1) apoptosis at the beginning of experiments was 
absent and 2) freshly prepared living donor explants followed a similar rate of cell 
death to post mortem explants. One possibility is that the mediums used did not 
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contain the necessary growth factors to maintain human RGC survival for such 
extended times and this warrants further investigation. Support for the assumption that 
medium composition is important for survival was shown in the experiments where 
explants displayed variations in the rate of neurodegeneration depending on medium 
composition.  
 
After we had identified that serum did not improve survival in human explants, we 
decided to test an alternative SF medium in the hope that this might enhance survival. 
We opted for the most commonly used medium composition for the survival of RGCs 
(Bull et al., 2011; Johnson and Martin, 2008) which is also a medium shown to 
enhance hippocampal neuron survival over 4 weeks in culture (Brewer, 1997); this 
was Neurobasal®-A with the stated supplements. However to our surprise, we 
observed a rapid loss of RGCs and increased early apoptosis in the HORCs cultured 
in Neurobasal medium compared to those in SF DMEM/F12 medium. The reason for 
the survival differences with the two media was unclear and beyond the scope of this 
paper, however we can speculate that differences in amino acids, vitamins, ferric 
nitrate and sodium pyruvate compositions might have played a role, particularly a lack 
of glutamate and aspartate in NB medium. Additionally, the B27 supplement in NB 
medium can suppress the growth of glial cells (Brewer et al., 1993), which may 
dampen the supportive role of these cells in human explants. Identification as to why 
NB was detrimental to human RGCs would be useful for future investigation although 
the result does itself highlight that cell soma delivered trophic factors are important in 
affecting RGC degeneration. 
 
4.4 Further uses of human explants 
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Although TUNEL labelling was only quantified in the RGC layer, an overall increase in 
TUNEL labelling could be seen throughout the retina. With apoptosis evident in the 
INL and ONL, and appearing to increase with time in culture, use of human organotypic 
cultures may prove useful in the study of other retinal diseases. Rat organotypic 
cultures, for example, are currently being used to measure growth factor 
neuroprotection of photoreceptors (Lipinski et al., 2011). Assessing novel 
neuroprotective strategies relating to retinal neurodegeneration of either 
photoreceptors (e.g. in age-related macula degeneration or retinitis pigmentosa) or 
RGCs (e.g. in glaucoma) could be a useful application for this model. 
 
5 Conclusions 
Strong similarity between human post mortem tissue and living donor retina suggest 
that human retinal explants could be a valuable resource as a chronic experimental 
model of RGC degeneration. Various markers can be used to accurately quantify RGC 
number throughout the retina and alterations to the medium can have an impact on 
the rate of apoptosis and cell loss. The human explant model therefore provides a 
platform to investigate future neuroprotective and regenerative therapies, which rely 
on delaying RGC apoptosis. 
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Fig. 1: Dissection of the human eye globe to create retinal explants. (A) A circular ring 
of tissue was removed approximately 10mm below the ciliary body. (B) The eye globe 
was rotated to dissociate the retina from the underlying retinal pigmented epithelium 
using the weight of the vitreous to separate the layers. (C) A single cut was performed 
at the optic nerve head to detach the retina. (D) The vitreous was then removed and 
the retina spread flat, retinal ganglion cell side up. (E) The macula was removed using 
a 4mm diameter dissecting trephine. The fovea (white arrow) at the center of the 
macula could be identified as a shallow depression containing yellow carotenoid 
pigments lutein and zeaxanthin that indicated accurate macula explant preparation 
(F). (G) Five 4mm para-macular samples were taken at equidistant locations from the 
macula using a template to reduce variability between dissections. 
 
Fig. 2: RGC gene expression was comparable between explants taken in the para-
macular region with the greatest expression of each marker within macular explants. 
(A) The dissection template was used to collect all explants and resulted in improved 
sampling reproducibility. (B) RBFOX3 (NeuN) mRNA expression in retinal explants 
(n=11 donor eyes). (C) TUB3 (βIII tubulin) mRNA expression in explants (n=11 donor 
eyes). (D) THY1 mRNA expression in explants (n=15 donor eyes). All mRNA was 
normalised to the expression of the housekeeping genes TOP1 and CYC1. Graphs 
show individual values for each explant including the mean ± s.e.m. Explants A-E are 
taken within the para-macular region of the retina, M are samples dissected at the 




Fig. 3: RGC gene expression was not significantly influenced by the age of the donor 
or the time between donor death and retinal explant creation (post mortem time). (A-
F) Each data point represents a single para-macular explant and indicated that there 
was no significant correlation between the expression of RBFOX3 (n=49 explants), 
TUB3 (n=49 explants) or THY1 (n=68 explants) with parameters that could influence 
RGC starting number. (G, H) THY1 expression from a larger cohort of untreated eyes 
(n=100 donor eyes) taken immediately after dissection similarly revealed no 
correlation between donor age, post mortem time and gene expression. All mRNA was 
normalised to the expression of the housekeeping genes TOP1 and CYC1. 
 
Fig. 4: Gene profiling revealed the location of RGC markers RBFOX3, TUB3 and 
THY1 throughout the retina in macular (A) and para-macular (B) explants. Up to 21x 
20µm sections were collected throughout the entire retinal thickness and processed 
in the plane of the retinal nuclear layers from the photoreceptor layer (left) to the retinal 
ganglion cell (RGC) layer (right). A greater number of sections were collected from 
macular explants due to the highest thickness in this region, with a broader RGC peak 
due to a denser, thicker RGC layer. Similar expression patterns were seen between 
RBFOX3, TUB3 and THY1 in both macular and para-macular regions. (RBFOX3 n=3 
donor eyes (for both macular and para-macular explants), TUB3 n=4 donor eyes, 
THY1 n=3 donor eyes; mean ± s.e.m). 
 
Fig. 5: Retinal ganglion cell (RGC) markers NeuN, βIII tubulin and Thy-1 labelled 
nuclei almost exclusively in the RGC layer of macular and para-macular explants (A-
C). Para-macular explants contained a single row of RGCs that stained positive for 
each marker whilst macular samples had a denser RGC layer with multiple rows of 
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NeuN, βIII tubulin and Thy-1 labelled cells. NeuN staining was located in the cell body 
(nucleus and surrounding cytoplasm), βIII tubulin labelled RGC soma and their 
processes and Thy-1 resulted in diffuse cell body staining. Scale = 50µm (n=4 donor 
eyes). 
 
Fig. 6: Co-localisation of NeuN and βIII tubulin in transverse (A, C) and whole-mount 
(B, D) sections revealed both markers were specifically labelling the same cell type in 
the RGC layer. Similar levels of co-localisation could be seen in macular and para-
macular regions of the retina. Scale = 50µm (n=5 donor eyes).  
 
Fig. 7: The survival of human retinal ganglion cells (RGCs) in ex vivo para-macular 
explants (HORCs) over 4 weeks. Representative immunofluorescence 
photomicrographs of HORCs cultured in SF medium at (A) 0 weeks post dissection, 
(B) 1 week, (C) 2 week, (D) 3 week, (E) 4 week. (F) The percentage of NeuN+ cells in 
the RGC layer (mean ± s.e.m; n=3-6 donor eyes) relative to same donor counts 
immediately post dissection. (G) The proportion of TUNEL+ NeuN+ cells in the RGC 
layer (mean ± s.e.m; n=3-6 donor eyes) with time in culture. (H) The change in THY1 
mRNA expression (mean ± s.e.m; n=2-6 donor eyes) with time in culture relative to 
same donor expression immediately after explant creation. DAPI = blue, NeuN = 
green, TUNEL = red. White arrows highlight TUNEL+ NeuN+ cells in the RGC layer. 
GCL = ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer. Red 
data points = Living donor explants cultured in SF medium. Scale = 50µm. *, †, ‡ 
indicates a statistically significant differences compared to samples processed 
immediately after dissection in SF, 10% FBS and Neurobasal (NB) medium 
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respectively. § indicates a significant difference between SF and NB results at the 
same time point. 
 
Table. 1: List of TaqMan probe/primer sets used in the experiments. 
 
Table. 2: The percentage of DAPI positive cells that stained positive for individual 
RGC markers in the RGCL (n=4 donor eyes).  
 
Table. 3: The percentage of NeuN labelled cells that were also βIII tubulin positive in 
macular and para-macular explants (n=5 donor eyes).  
 
Supplementary Fig. 1: Gene profiling of the RGC marker THY1 (A) and the 
cholinergic amacrine marker ChAT (B) throughout macula explants revealed 
differences in the location of maximal gene expression. THY1 peaked in the inner 
retina whereas ChAT expression was detected at greatest levels within the inner 






Gene Number/Sequence Supplier 
RBFOX3 Hs01370653_m1 Applied Biosystems, Warrington, UK 
TUB3 Hs00801390_s1 Applied Biosystems, Warrington, UK 
THY1 Hs00174816_m1 Applied Biosystems, Warrington, UK 
TOP1 HK-DD-hu-300 Primer Design, Southampton, UK 















 NeuN βIII tubulin Thy-1 
Macular 82.7±1.9% 80.9±2.6% 81.8±1.5% 
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